The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo

British Journal of Cancer

Volumn 96, Issue 10, 2007, Pages 1532-1539

  Akashi, Y ^a   Okamoto, I ^a   Suzuki, M ^b   Tamura, K ^c   Iwasa, T ^a   Hisada, S ^d   Satoh, T ^a   Nakagawa, K ^a   Ono, K ^b   Fukuoka, M ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KINDAI UNIVERSITY NARA HOSPITAL   (Japan)

^d Asuka Pharmaceutical Co Ltd   (Japan)

Author keywords

Antivascular effect; Apoptosis; Microtubule; Mitotic arrest; Radiosensitisation; TZT 1027

Indexed keywords

AURISTATIN PE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL CYCLE PROGRESSION; CLONOGENESIS; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL NEOPLASM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; LUNG CARCINOMA; MICROTUBULE ASSEMBLY; MITOSIS; MITOSIS INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; SINGLE DRUG DOSE; TUMOR NECROSIS; VASCULAR ENDOTHELIUM;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL CYCLE; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, NUDE; MICROTUBULES; MODELS, BIOLOGICAL; OLIGOPEPTIDES; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34248581988     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603769     Document Type: Article

References (6)

1. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ (2002) Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8: 1974-1983
2. Choy H, Yee L, Cole BF (1995) Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation. Semin Oncol 22: 38-44
3. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829- 1834
4. de Jonge MJ, van der Gaast A, Planting AS, van Doorn L, Lems A, Boot I, Wanders J, Satomi M, Verweij J (2005) Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin Cancer Res 11: 3806- 3813
5. Edelstein MP, Wolfe III LA, Duch DS (1996) Potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer. Semin Oncol 23: 41-47
6. Goodin S, Kane MP, Rubin EH (2004) Epothilones: mechanism of action and biologic activity. J Clin Oncol 22: 2015-2025